| Page 12 | Cafepharma

You are here

Primary tabs

UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market

Post date: May 15, 2018 - 9:18am

Celsius Therapeutics Launches with $65 Million Series A to Develop Autoimmune and Cancer Precision Therapies

Post date: May 15, 2018 - 9:08am

CRISPR Focused Intellia Therapeutics Adds Scientific Advisors in Immuno-Oncology and Autoimmunity

Post date: May 14, 2018 - 10:03am

Gene Editing Pioneers Launch Beam Therapeutics With $87 Million Series A Round

Post date: May 14, 2018 - 9:14am

Briviact (Brivaracetam) Wins Approval to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients

Post date: May 14, 2018 - 8:57am

Synaffix Adds Antibody Drug Conjugate Veteran John Lambert to Scientific Advisory Board

Post date: May 14, 2018 - 8:43am

Phage-Based Therapy - A Primer

Post date: May 11, 2018 - 10:04am

AstraZeneca's Fasenra (benralizumab) Fails Ph III Trial for COPD

Post date: May 11, 2018 - 9:52am

Krystal Biotech Doses First Patient in Phase 1/2 trial of KB103 Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa

Post date: May 11, 2018 - 9:27am

FDA Advisory Committee Votes in Favor of Waylivra for Treatment of Familial Chylomicronemia Syndrome

Post date: May 11, 2018 - 9:20am

Pages